YF476 and Type II Gastric Carcinoids

NCT02454075 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Poor recruitment

Conditions

Zollinger-Ellison Syndrome

Interventions

DRUG: YF476

Sponsor

Trio Medicines Ltd.

Collaborators

[object Object]